| Screening | Baseline/Randomisation (T0) | After 4 interventions (T1) |  |  | After 16 interventions (T2) |
---|---|---|---|---|---|---|
 | 0 wk | 2 wk | 4 wk | 6 wk | 8 wk | |
HTB/PEP target (n)a | Â | Â | 4 | 8 | 12 | 16 |
HAM-Db | x | x | x | Â | Â | x |
Medical history | Â | x | Â | Â | Â | Â |
BDI-IIc | Â | x | x | Â | Â | x |
PSQId | Â | x | x | Â | Â | x |
Global judgement of efficacy | Â | Â | x | Â | Â | x |
Global judgement of tolerability | Â | Â | x | Â | Â | x |
Change of medication/therapy | Â | Â | x | Â | Â | x |
Adverse eventse | Â | Â | x | x | x | x |
Telephone contact | Â | Â | Â | x | x | Â |